As a new next-generation immunotherapeutic agent, ADCs are being developed globally as a primary strategy to battle against cancer and other immunological illnesses. Herein, a great number of ADCs are being innovated for clinical trial pipelines. Nevertheless, significant challenges hinder the progress of researchers, such as selecting a good target, a suitable linker, and producing an antibody with high affinity and internalization capability upon binding. This document introduced a list of FDA-approved ADCs and provided a thorough analysis of international ADC clinical trials as well as our outlook on trends in the next ADC advancements.

The following list includes the major topics of this brochure:

1. Overview of the FDA-approved ADCs
2. Overview of ADCs in Clinical Trials
3. Selected Targets for ADCs in Clinical Trials
4. Indications
5. Status of ADCs Clinical Trials
6. Companies and Institutions
7. Summary and Outlooks